g., infliximab that targets the tumor necrosis factor (TNF) pathway, are broadly immunosuppressive with major side effects including a higher risk of non-Hodgkin’s lymphoma [33]. The gene discussed is TNF; the disease is non-Hodgkin lymphoma.